Ewing Sarcoma – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Ewing Sarcoma – Pipeline Review, H1 2017’, provides an overview of the Ewing Sarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ewing Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Ewing Sarcoma

The report reviews pipeline therapeutics for Ewing Sarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Ewing Sarcoma therapeutics and enlists all their major and minor projects

The report assesses Ewing Sarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Ewing Sarcoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ewing Sarcoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ewing Sarcoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amgen Inc

Astellas Pharma Inc

Bristol-Myers Squibb Company

Cebiotex SL

Celgene Corp

Celldex Therapeutics Inc

CytRx Corp

EntreChem SL

Gradalis Inc

Incyte Corp

Leadiant Biosciences Inc

MacroGenics Inc

Merck & Co Inc

Merrimack Pharmaceuticals Inc

NanoSmart Pharmaceuticals Inc

NantKwest Inc

Novartis AG

Oncomatryx Biopharma SL

Oncternal Therapeutics Inc

Pfizer Inc

Pharma Mar SA

Recombio SL

Shionogi & Co Ltd

Tarveda Therapeutics Inc

Tesaro Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 4

Ewing Sarcoma - Overview 5

Ewing Sarcoma - Therapeutics Development 6

Ewing Sarcoma - Therapeutics Assessment 14

Ewing Sarcoma - Companies Involved in Therapeutics Development 24

Ewing Sarcoma - Drug Profiles 38

Ewing Sarcoma - Dormant Projects 239

Ewing Sarcoma - Discontinued Products 240

Ewing Sarcoma - Product Development Milestones 241

Appendix 249

List of Tables

List of Tables

Number of Products under Development for Ewing Sarcoma, H1 2017 11

Number of Products under Development by Companies, H1 2017 13

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 14

Number of Products under Development by Universities/Institutes, H1 2017 15

Products under Development by Companies, H1 2017 16

Products under Development by Companies, H1 2017 (Contd..1), H1 2017 17

Products under Development by Universities/Institutes, H1 2017 18

Number of Products by Stage and Target, H1 2017 20

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 21

Number of Products by Stage and Mechanism of Action, H1 2017 23

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 24

Number of Products by Stage and Route of Administration, H1 2017 26

Number of Products by Stage and Molecule Type, H1 2017 28

Ewing Sarcoma – Pipeline by Amgen Inc, H1 2017 29

Ewing Sarcoma – Pipeline by Astellas Pharma Inc, H1 2017 29

Ewing Sarcoma – Pipeline by Bristol-Myers Squibb Company, H1 2017 30

Ewing Sarcoma – Pipeline by Cebiotex SL, H1 2017 30

Ewing Sarcoma – Pipeline by Celgene Corp, H1 2017 31

Ewing Sarcoma – Pipeline by Celldex Therapeutics Inc, H1 2017 32

Ewing Sarcoma – Pipeline by CytRx Corp, H1 2017 32

Ewing Sarcoma – Pipeline by EntreChem SL, H1 2017 33

Ewing Sarcoma – Pipeline by Gradalis Inc, H1 2017 33

Ewing Sarcoma – Pipeline by Incyte Corp, H1 2017 34

Ewing Sarcoma – Pipeline by Leadiant Biosciences Inc, H1 2017 35

Ewing Sarcoma – Pipeline by MacroGenics Inc, H1 2017 35

Ewing Sarcoma – Pipeline by Merck & Co Inc, H1 2017 36

Ewing Sarcoma – Pipeline by Merrimack Pharmaceuticals Inc, H1 2017 36

Ewing Sarcoma – Pipeline by NanoSmart Pharmaceuticals Inc, H1 2017 37

Ewing Sarcoma – Pipeline by NantKwest Inc, H1 2017 37

Ewing Sarcoma – Pipeline by Novartis AG, H1 2017 38

Ewing Sarcoma – Pipeline by Oncomatryx Biopharma SL, H1 2017 38

Ewing Sarcoma – Pipeline by Oncternal Therapeutics Inc, H1 2017 39

Ewing Sarcoma – Pipeline by Pfizer Inc, H1 2017 39

Ewing Sarcoma – Pipeline by Pharma Mar SA, H1 2017 40

Ewing Sarcoma – Pipeline by Recombio SL, H1 2017 41

Ewing Sarcoma – Pipeline by Shionogi & Co Ltd, H1 2017 41

Ewing Sarcoma – Pipeline by Tarveda Therapeutics Inc, H1 2017 42

Ewing Sarcoma – Pipeline by Tesaro Inc, H1 2017 42

Ewing Sarcoma – Dormant Projects, H1 2017 244

Ewing Sarcoma – Discontinued Products, H1 2017 245

List of Figures

List of Figures

Number of Products under Development for Ewing Sarcoma, H1 2017 11

Number of Products under Development by Companies, H1 2017 12

Number of Products under Development by Universities/Institutes, H1 2017 15

Number of Products by Top 10 Targets, H1 2017 19

Number of Products by Stage and Top 10 Targets, H1 2017 19

Number of Products by Top 10 Mechanism of Actions, H1 2017 22

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017 22

Number of Products by Routes of Administration, H1 2017 25

Number of Products by Stage and Routes of Administration, H1 2017 25

Number of Products by Molecule Types, H1 2017 27

Number of Products by Stage and Molecule Types, H1 2017 27

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports